Novavax, Inc. (NASDAQ:NVAX - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $7.00, but opened at $6.49. Novavax shares last traded at $6.56, with a volume of 1,039,722 shares trading hands.
Analyst Ratings Changes
A number of brokerages have recently issued reports on NVAX. HC Wainwright restated a "buy" rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. TD Cowen upgraded shares of Novavax to a "hold" rating in a research note on Thursday, February 27th. Finally, BTIG Research assumed coverage on shares of Novavax in a research note on Friday, February 28th. They set a "buy" rating and a $19.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $18.00.
Read Our Latest Stock Analysis on NVAX
Novavax Trading Down 0.3 %
The company has a market cap of $961.85 million, a price-to-earnings ratio of -2.65, a PEG ratio of 2.85 and a beta of 2.92. The company's 50 day moving average price is $7.98 and its 200 day moving average price is $9.21.
Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million during the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) EPS. Sell-side analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of NVAX. Vanguard Group Inc. boosted its position in shares of Novavax by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock worth $126,439,000 after purchasing an additional 296,181 shares in the last quarter. Shah Capital Management boosted its holdings in Novavax by 13.6% during the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after buying an additional 1,333,305 shares in the last quarter. State Street Corp grew its position in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock worth $97,099,000 after buying an additional 1,621,772 shares during the period. Sanofi purchased a new position in Novavax in the fourth quarter valued at about $55,319,000. Finally, Geode Capital Management LLC lifted its position in shares of Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock valued at $29,415,000 after acquiring an additional 155,206 shares during the period. Institutional investors and hedge funds own 53.04% of the company's stock.
About Novavax
(
Get Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Featured Stories
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
